Company Encyclopedia
View More
name
Neurogene
NGNE.US
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.
1.946 T
NGNE.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking236/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-42.25%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-2498.60%E
    • Total Assets YoY75.38%A
    • Net Assets YoY93.24%A
  • Cash ScoreE
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio7.74%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Neurogene Grants Stock Options to New Employees Under 2025 Inducement Plan

    Neurogene Inc. has granted non-qualified stock options to two new employees, allowing them to purchase a total of 4,860 shares of the company's common stock. These options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly over the next three years, contingent on continued employment.

    Reuters·
    US
    NGNE
    +5.17%
    Reuters·
    US
    NGNE
    +5.17%

    SA Quant ranks Goldman's small-cap stocks with largest short interest

    Goldman Sachs identified 50 small-cap stocks with high short interest, topped by Anavex Life Sciences. Seeking Alpha ranked these stocks using its Quant Rating system, with AnaptysBio leading with a Strong Buy rating of 4.89. Neurogene follows with a Buy rating of 4.00. Most stocks are rated Hold, including Bit Digital and Cable One. Ratings are based on valuation, growth, profitability, and momentum, with scores above 3.5 considered bullish.

    MSN·
    US
    NGNE
    +5.17%
    US
    ANAB
    -1.05%
    US
    AVXL
    -2.63%
    MSN·
    US
    NGNE
    +5.17%
    US
    ANAB
    -1.05%
    US
    AVXL
    -2.63%

    Neurogene Inc. Reports Q3 2025 Financial Results

    Neurogene Inc. reported a Q3 2025 net loss of $20.95 million, with operating expenses of $23.8 million. Cash decreased to $71 million, while short-term investments rose to $194.4 million. Despite losses, management is optimistic, expecting cash and investments to support operations for another year. The company plans to advance clinical programs and explore strategic partnerships to enhance financial stability.

    Tip Ranks·
    US
    NGNE
    +5.17%
    Tip Ranks·
    US
    NGNE
    +5.17%

    Neurogene’s NGN-401: Strong Clinical Results and Market Misalignment Justify Buy Rating

    H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene, setting a $70 price target. The strong clinical results of NGN-401, especially for Rett syndrome, show significant improvements, yet the market undervalues it due to misinterpretations. Kapoor views the recent selloff as narrative noise, not reflective of NGN-401's potential. Insights from Dr. David Lieberman highlight its safety and long-term benefits, supporting Kapoor's positive outlook.

    Tip Ranks·
    US
    NGNE
    +5.17%
    Tip Ranks·
    US
    NGNE
    +5.17%

    Neurogene Inc. unveils corporate presentation highlighting gene therapy advances for Rett syndrome and rare neurological diseases

    Neurogene Inc. has released a corporate presentation detailing updates on its clinical pipeline for rare neurological diseases. The lead program, NGN-401 for Rett syndrome, shows promising interim clinical data with ongoing trials. Enrollment is expected to complete in 3-6 months. The company also highlighted its manufacturing capabilities and updates on NGN-101 for CLN5 Batten Disease. Full presentation available online.

    Reuters·
    US
    NGNE
    +5.17%
    Reuters·
    US
    NGNE
    +5.17%
    © 2025 Longbridge｜Disclaimer